Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, has appointed Drayton Wise as chief commercial officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Wise will assume responsibility for all of Insmed’s global commercial functions. Wise will also serve as a member of Insme...